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A B S T R A C T   
Background: Cardiac magnetic resonance imaging (MRI) is emerging as an important imaging tool in the 
assessment of heart failure with preserved ejection fraction (HFpEF). This systematic review and meta-analysis 
aim to synthesise and consolidate the current literature on cardiac MRI for prognostication of HFpEF. 
Methods design: Systematic review and meta-analysis. Data sources: Scopus (PubMed and Embase) for studies 
published between 2008 and 2019. Eligibility criteria for study selection were studies that evaluated the prog-
nostic role of cardiac MRI in HFpEF. Random effects meta-analyses of the reported hazard ratios (HR) for clinical 
outcomes was performed. 
Results: Initial screening identified 97 studies. From these, only nine (9%) studies met all the criteria. The main 
cardiac MRI methods that demonstrated association to prognosis in HFpEF included late gadolinium enhance-
ment (LGE) assessment of scar (n = 3), tissue characterisation with T1-mapping (n = 4), myocardial ischaemia (n 
= 1) and right ventricular dysfunction (RVSD) (n = 1). The pooled HR for all 9 studies was 1.52 (95% CI 
1.05–1.99, P < 0.01). Sub-evaluation by cardiac MRI methods revealed varying HRs: LGE (net n = 402, HR = 1.6, 
95% CI 0.42–2.78, P = 0.008); T1-mapping (n = 1623, HR = 1.25, 95% CI 0.891–1.60, P < 0.001); myocardial 
ischaemia or RVSD (n = 325, HR = 3.19, 95% CI 0.30–6.08, P = 0.03). 
Conclusion: This meta-analysis demonstrates that multiparametric cardiac MRI has value in prognostication of 
patients with HFpEF. HFpEF patients with a detectable scar on LGE, fibrosis on T1-mapping, myocardial 
ischaemia or RVSD appear to have a worse prognosis. 
PROSPERO registration number: CRD42020187228.   
1. Introduction 
Heart failure with preserved ejection fraction (HFpEF) accounts for 
over 50% of all heart failure cases [1]. HFpEF is a clinical syndrome in 
which the heart is incapable of delivering enough oxygen to the tissues 
proportionate with their metabolic demands while the contraction is not 
impaired [2]. It is associated with poor quality of life, significantly more 
need for medical attention, and a higher risk of premature death [3]. 
HFpEF’s pathophysiology is still broadly unknown, which partly ex-
plains why there is no specific treatment for it. The prevalence of HFpEF 
is increasing and leading to an emerging epidemic with increased 
morbidity and mortality ranging from 10% to 30% annually and is 
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higher in epidemiological studies than in clinical trials. The major causes 
of death in HFpEF are cardiovascular, making up 51–60% of deaths in 
epidemiological studies and > 70% in clinical trials [4]. 
Although transthoracic echocardiography (TTE) remains the pri-
mary diagnostic tool for HFpEF, cardiac magnetic resonance imaging 
(MRI) is the recognised gold standard for the assessment of left ven-
tricular (LV) systolic function, confirming left atrial enlargement and LV 
hypertrophy [5]. In addition to volumetric assessment, multiparametric 
cardiac MRI tissue characterisation and first-pass perfusion can further 
sub-phenotype patients with HFpEF [6]. This is becoming more relevant 
as for certain HFpEF sub-phenotypes, there are emerging therapies [7]. 
Late gadolinium enhancement (LGE) imaging by cardiac MRI is a 
valuable tool for scar detection [8]. Beyond focal scar lesions, illustrated 
by LGE imaging methods, native and post-contrast T1 mapping can 
recognise diffuse myocardial fibrosis, previously not feasible by nonin-
vasive techniques (Fig. 1) [9]. Myocardial ischaemia assessment by first- 
pass perfusion cardiac MRI is non-inferior to invasive quantitative 
ischaemia evaluation with respect to major adverse cardiac events 
(MACE) [10]. 
Previously published studies have focused more on the diagnostic 
value of cardiac MRI in HFpEF, while the overall prognostic utility of 
cardiac MRI remains unclear. In addition, it is not clear which cardiac 
MRI method has the most evidence to guide prognosis in HFpEF. Sys-
tematic evidence synthesis is required to develop further understanding 
of which cardiac MRI methods are clinically applicable to predict 
prognosis in HFpEF. The aim of this systematic review and meta-analysis 
was, therefore, to summarise current literature, systematically consoli-
date studies which have evaluated the role of cardiac MRI in prognos-
tication of HFpEF. 
2. Methods 
2.1. Systematic review and meta-analysis registration 
This project was prospectively registered (CRD42020187228) [11] 
with the prospective register of systematic review (PROSPERO), the 
international database of prospectively registered systematic reviews 
and meta-analyses in health, where there is a health-related outcome. 
Fig. 1. Multiparametric cardiac magnetic resonance imaging in patients with HFpEF. In this particular case, there is evidence of concentric left ventricular hy-
pertrophy with an LV ejection fraction of 62%. Also, there is evidence of perfusion defect during first-pass perfusion (orange arrows). T1-mapping shows a global 
pattern of rise in values. ECV mapping demonstrates large areas of the myocardium with an ECV of 30% to 50% (yellow area) and also >50% (red areas of the 
myocardium). A similar pattern of fibrosis was seen on LGE imaging. (For interpretation of the references to colour in this figure legend, the reader is referred to the 
web version of this article.) 
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2.2. Eligibility criteria 
Studies which assessed the prognostic significance of cardiac MRI in 
HFpEF were included. The primary outcomes of interest were HF hos-
pitalisation and all-cause mortality. This systematic review and meta- 
analyses mainly focused on the hazard ratio (HR) for outcomes, and 
all subsequent meta-analyses were planned using HR and standard error 
values. We limited our search to full articles, medicine, and human 
participants. Studies that were not published in English were excluded. 
Ethics approval was not required, as no patients were involved. 
2.3. Search strategy and study selection 
The literature search was done on the Scopus database. This database 
incorporates all Medline and Embase results. The initial screening was 
done by HA, RJ and PG on 21/11/2019, followed by a second screening 
on 15/10/2020, and included the following terms: (TITLE-ABS-KEY 
(heart AND failure AND with AND preserved AND ejection AND frac-
tion) OR TITLE-ABS-KEY (hfpef) AND TITLE-ABS-KEY (cardiac AND 
magnetic AND resonance AND imaging) OR TITLE-ABS-KEY (cardiac 
AND mri) AND TITLE-ABS-KEY (prognosis) OR TITLE-ABS-KEY 
(outcome)). We also searched manually the reference lists of relevant 
studies. All searches were integrated and duplicates were removed. 
PRISMA guidelines were used for the identification, screening, in-
clusion and selection of studies. The final shortlist of included studies 
was reviewed and approved by two independent assessors, PG and AAM. 
Fig. 2 details the search strategy, using the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) tool [12]. 
2.4. Statistical analysis 
Statistical analysis was performed using MedCalc (MedCalc Soft-
ware, Ostend, Belgium version 19.1.5). Graphing was undertaken in 
Origin Lab Pro (Origin Lab Corp., Northampton, MA), and Lucidchart 
diagram (Lucid Software Inc., Utah, USA). We pooled the values of HR 
for clinical outcomes and the number of patients recruited in each study. 
The inverse variance method was used to calculate the weighted sum-
mary HRs under the random-effects model. In the inverse variance 
method, the weight given to each study is the inverse of the variance of 
the effect estimate (i.e. one over the square of its standard error). Thus, 
larger studies are given more weight than smaller studies, which have 
larger standard errors. This choice of weight minimises the imprecision 
(uncertainty) of the pooled effect estimate. Next, the heterogeneity 
statistics were incorporated to calculate the summary correlation coef-
ficient under the random-effects model with 95% confidence interval 
(CI) was used in all analyses. The main findings of the meta-analysis 
were presented as Forest plots and tables. We used the I2 statistic to 
measure heterogeneity among the trials in each analysis and used a 
threshold of 75% as significantly heterogeneous. 
3. Results 
After an initial screening of 97 research studies, nine studies were 
identified and included in the systematic review and meta-analysis. For 
each study, we identified the number of patients involved; the primary 
cardiac MRI method used; the follow-up period and the clinical out-
comes with the hazard ratio for cardiac MRI variables to predict out-
comes. From the initial results, 88 studies were excluded for not meeting 
our inclusion criteria. Seven included studies were prospective single- 
centre observational cohorts [6,13–18], and two studies were retro-
spective single-centre observational cohorts [19,20]. Analysts in all 
studies were blinded to cardiac MRI results. The mean age was 63 ± 21, 
and 1084 (46%) patients were males. The total number of patients 
included was 2350, and the median follow up period ranged between 
7.5 and 48 months. The assessed clinical outcomes included heart failure 
hospitalisations, cardiac transplantations, and death. A summary of 
baseline characteristics, outcomes, cardiac MRI metrics, and their sig-
nificance of the nine studies included in the systematic review and meta- 
analyses is detailed in Table 1 and Table 2. 
3.1. Meta-analysis 
The studies were divided into three groups by cardiac MRI method: 
late gadolinium enhancement scar imaging, T1 mapping and other 
relaxometry techniques, and other cardiac MRI methods including 
ischaemia assessment. The pooled analysis across all cardiac MRI 
methods showed a total random effect of 1.52 (SE = 0.24, 95% CI 
1.05–1.99, P < 0.001, z = 6.3) (Fig. 3). The strongest study was that by 
Kato et al. [13], who recruited 111 patients and found a high HR of 7.91 
(SE = 2.01, 95% CI 3.96–11.87). This study was included in the LGE 
group, which overall had a total random effect of 1.60 (SE = 0.60, 95% 
CI 0.42–2.78, P = 0.008, z = 2.66). 
The second group consisted of four studies focusing on tissue char-
acterisation and had a total random effect of 1.25 (SE = 0.18, 95% CI 
0.891–1.60, P < 0.001, z = 6.91). The study with the lowest hazard ratio 
was that by Mascherbaur et al. [14] (HR = 0.99, SE = 0.25, 95% CI 
0.50–1.49). The study with the highest HR was that by Schelbert et al. 
[15] (HR = 1.75, SE = 0.45, 95%CI 0.88–1.63) and was also the largest 
study of the whole cohort, recruiting 1174 patients. 
The final group consisted of two studies using cardiac MRI to assess 
either myocardial ischaemia or right ventricular function. The total 
random effect was the highest of the three groups, at 3.19 (SE = 1.47, 
95% CI 0.30–6.08, P = 0.03, z = 2.16). 
A strong correlation between the right heart and prognosis in HFpEF 
was reported by Aschauer et al. [16]. Of the 171 patients with HFpEF, 33 
patients (19.3%) had right ventricular systolic dysfunction (RVSD) 
(right ventricular ejection fraction [RVEF] <45%) by cardiac MRI and 
were followed up for (19.1 ± 12.9) months. During this time, 19 of these 
patients (57.6%) reached the primary endpoint (death/HF hospital-
isation). In comparison with patients without RVSD, by univariable and 
multivariable Cox analysis, RVSD was markedly linked with reduced 
event-free survival (HR = 4.90, 95% CI 2.46–9.75, P < 0.001). Nested 
Cox regression models established the mortality rate of RVSD by cardiac 
MRI (HR 5.05, 95% CI 1.82–13.95, P = 0.002). RVSD was the most 
Fig. 2. Flow diagram demonstrating evidence synthesis for the systematic re-
view, adapted from Moher et al. 2009 [12] using the PRISMA tool. 
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potent prognosticator of death. 
4. Discussion 
This meta-analysis demonstrated that cardiac MRI derived markers 
can predict the prognosis and outcome of patients with HFpEF by 
unmasking potential clinically undiagnosed underlying heart diseases, 
and identifying structural changes in the myocardium that could 
adversely affect the prognosis in several patients. These markers include 
myocardial late gadolinium enhancement usually signifying myocardial 
scarring, tissue characterisation by native and post-contrast T1 mapping 
which usually detect myocardial fibrosis, stress cardiac MRI which de-
tects underlying myocardial ischaemia, and volumetric right ventricular 
assessment on cines for RVSD. 
4.1. Late gadolinium enhancement scar imaging 
LGE for prognostication in HFpEF was first introduced in 2015 by 
Kato et al. [13]. They found LGE in 40 patients (36%) of their 111 pa-
tients. During follow up, 10 of the 111 patients (9%) experienced major 
adverse cardiovascular events, including death. Interestingly, eight of 
these ten patients were in the LGE+ group. Assessing the predictors of 
mortality by multivariate Cox proportional hazard analysis, they found 
that percentage of scar by LGE imaging independently predicted future 
events after the adjustment with age, presence of DM, New York Heart 
Association (NYHA) classification, history of HF hospitalisation, and 
LVEF which could explain the high HR. They demonstrated that 6% 
Table 1 
Summary of baseline characteristics and outcomes of studies included in the systematic review and meta-analysis.  
First author Year N Age (yrs) Male sex LVEF % FU Clinical outcome 
Late gadolinium enhancement scar imaging 
Murtagh G. 2016 205 56 ± 7 64 (31) 61 ± 6 7.5 8 deaths and 4 HF hospitalisations 
Kato S. 2015 111 70 ± 14 56 (50) 61 ± 10 28.3 ± 20.3 2 deaths and 6 HF hospitalisations 
Pöyhönen P. 2014 86 52 ± 10 47 (55) 50 27.8 13 deaths and 2 cardiac transplantations  
T1-mapping and other relaxometry techniques 
Kanagala P. 2019 232 73 ± 8 67 (49) 56 ± 6 47.6 14 deaths and 28 HF hospitalisations 
Schelbert E.B. 2017 1174 55 ± 11 637 (54) 62 23.1 48 deaths and 13 HF hospitalisations 
Duca F. 2016 117 74 ± 8 36 (31) 64 ± 10 24 4 deaths and 30 HF hospitalisations 
Mascherbauer J. 2013 100 70 ± 7 38 (40) 64 ± 11 22.9 ± 5 3 deaths and 13 HF hospitalisations  
Others CMR methods including ischaemia assessment 
Kanagala P. 2018 154 72 ± 10 78 (51) 57 ± 6 20.7 19 deaths and 43 HF hospitalisations 
Aschauer S. 2016 171 70 ± 9 61 (35) 63 ± 9 19.1 ± 12.9 15 deaths and 26 HF hospitalisations 
Abbreviations: FU, follow-up (in months); HF, heart failure; LVEF, left ventricular ejection fraction. 
Table 2 
Summary of Cardiac MRI metric and their significance for studies included in 
this systematic review and meta-analysis.  
First author Cardiac MRI metric HR, 95% CI P-value 
Late gadolinium enhancement scar imaging 
Murtagh G. LGE 1.14, 1.09–1.18 <0.01 
Kato S. LGE 7.913, 1.603–39.05 0.012 
Pöyhönen P. LGE 1.027, 1–1.04 0.003  
T1-mapping and other relaxometry techniques 
Kanagala P. iECV 1.689, 1.141–2.501 0.009 
Schelbert E.B. ECV 1.75, 1.25–2.45 0.001 
Duca F. ECV 1.099, 1.005–1.201 0.038 
Mascherbauer J. Native-T1 0.99, 0.98–0.99 0.046  
Others CMR methods including ischaemia assessment 
Kanagala P. Stress cardiac MRI 1.92, 1.07–3.45 0.03 
Aschauer S. RVSD 4.90, 2.46–9.75 <0.001 
Abbreviations: CI, confidence interval; ECV, extracellular volume; HR, hazard 
ratio; iECV, total extracellular volume of the myocardium indexed to body 
surface area; LGE, late gadolinium enhancement; MOLLI, modified look-locker 
inversion; MRI, magnetic resonance imaging; RVSD, right ventricular systolic 
dysfunction. 
Fig. 3. Forest plot of pooled hazard ratio (HR) for all the studies with weighted random-effects model HR (1.518, 95% CI 1.05 to 1.99) in favour of cardiac MRI 
assessment for prognostication of HFpEF patients. 
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burden of LV scar tissue had a sensitivity of 80% and specificity of 77% 
to predict events. The Kaplan-Meier curves stratified by the presence and 
size of LGE demonstrated a significant impact on the prognosis of pa-
tients with HFpEF (P = 0.016 by Log-rank test). 
Murtagh et al. [20] used cardiac MRI derived LGE in the cardiac risk 
stratification of patients with extracardiac sarcoidosis. LGE was present 
in 41 patients (20%). Among the 205 patients in the cohort, 12 patients 
(6%) died or had ventricular tachycardia (VT), 10 of these 12 patients 
(83%) were in the LGE+ group. Murtagh et al. estimated that the death/ 
VT rate per year was 20% higher in the LGE+ group than the LGE−
group (4.9% vs 0.2%, P < 0.01). The percentage of scar quantified by 
LGE that predicted the risk of death/VT events and for recognising pa-
tients with myocardial damage despite having a preserved ejection 
fraction was 5.7%, with sensitivity and specificity of 87% and 62% 
respectively. Interestingly, their findings are similar to the findings by 
Kato et al. 
In another study, Pöyhönen et al. [19] evaluated the value of LGE 
imaging in patients suspected with non-ischaemic cardiomyopathy 
(NICM). Even though this study was not directly in patients with HFpEF, 
it was included in this systematic review as the mean left ventricular 
ejection fraction (LVEF) was 52%. In this study, the event rate for MACE 
was 26% in patients with LGE+ versus 4% in patients without LGE (P =
0.041). Of the 86 patients involved, 15 reached the endpoint (17%), 
with an event rate of 7.6% per year. The highest event rate was observed 
in patients with LGE volume of ≥17%. Thus, the presence of LGE while 
not essential in the cardiac MRI diagnosis of HFpEF appears to define the 
patients with a higher risk of major cardiovascular events, including 
death (Table 3). 
4.2. T1 mapping and other relaxometry techniques 
While LGE can only identify focal fibrosis, cardiac MRI T1 mapping 
can uncover and quantify diffuse fibrosis and has the potential to 
identify focal fibrosis as well in the myocardium [21–23]. Both native 
and post-contrast T1 mapping has proved reliability in the diagnosis of 
cardiomyopathies; in predicting their prognosis, and in directing their 
further treatment. Schelbert et al. [15] that increased extracellular 
volume (ECV) was associated with a high mortality rate in patients with 
HFpEF (HR = 1.75 per 5% increase in ECV, 95% CI 1.25–2.45, P =
0.001). Mascherbauer et al. [14] abnormal cardiac MRI T1 mapping in 
61 patients with HFpEF. During follow up, 16 (26.2%) patients reached 
the primary endpoint (three patients died, and 13 had HF hospital-
isations). Post-contrast T1 time was associated with the endpoint (HR =
0.99, 95% CI 0.98–0.99, P = 0.046). In histopathology, T1 time notably 
corresponded with extracellular matrix area in LV biopsy samples taken 
from patients and was strongly linked with the outcome. 
Duca et al. [17], measured myocardial ECV by cardiac MRI T1 
mapping using the modified look-locker inversion recovery (MOLLI) 
sequence and validated it against histology in a subset of their patient’s 
cohort for the prognostication of HFpEF. During follow-up for a median 
of 24 months, 34 (29%) of 117 patients reached the primary endpoint 
(four deaths and 30 HF hospitalisations). By multivariable Cox regres-
sion analysis, MOLLI-ECV was associated with outcome among imaging 
variables (HR = 1.099, 95% CI 1.01–1.2, P = 0.038). Moreover, the 
histological ECV (30.1 ± 4.6%) significantly correlated with MOLLI-ECV 
(r = 0.494, P = 0.037). In their study, patients with higher MOLLI-ECV 
had shorter event-free survival (Log-rank test: P = 0.028). Kanagala 
Table 3 
Results of group wise meta-analysis of cardiac MRI methods.  
Study HR SE 95% CI z P Weight (%) 
Late gadolinium enhancement scar imaging 
Murtagh G. 1.14 0.291 0.570 to 1.710   45.75 
Kato S. 7.913 2.019 3.956 to 11.870   7.55 
Pöyhönen P. 1.027 0.262 0.514 to 1.540   46.7 
Total (fixed effects) 1.141 0.194 0.761 to 1.520 5.887 <0.001 100 
Total (random effects) 1.598 0.601 0.421 to 2.776 2.662 0.008 100 
Test for heterogeneity       
Q 11.4438      
DF 2      
Significance level P = 0.0033      
I2 (inconsistency) 82.52%      
95% CI for I2 46.43 to 94.30       
T1-mapping and other relaxometry techniques 
Kanagala P. 1.689 0.431 0.845 to 2.533   15.61 
Schelbert E.B. 1.75 0.446 0.875 to 2.625   14.65 
Duca F. 1.099 0.28 0.549 to 1.649   32.12 
Mascherbauer J. 0.99 0.253 0.495 to 1.485   37.62 
Total (fixed effects) 1.221 0.161 0.906 to 1.536 7.606 <0.001 100 
Total (random effects) 1.245 0.18 0.892 to 1.599 6.906 <0.001 100 
Test for heterogeneity       
Q 3.6099      
DF 3      
Significance level P = 0.3068      
I2 (inconsistency) 16.90%      
95% CI for I2 0.00 to 89.27       
Others CMR methods including ischaemia assessment 
Kanagala P. 1.92 0.49 0.960 to 2.880   57.45 
Aschauer S. 4.9 1.25 2.450 to 7.350   42.55 
Total (fixed effects) 2.317 0.456 1.423 to 3.210 5.08 <0.001 100 
Total (random effects) 3.188 1.473 0.300 to 6.076 2.164 0.03 100 
Test for heterogeneity       
Q 4.927      
DF 1      
Significance level P = 0.0264      
I2 (inconsistency) 79.70%      
95% CI for I2 12.50 to 95.29      
Abbreviations: CI, confidence interval; DF, degree of freedom; FU, follow-up (in months); HR, hazard ratio; MRI, magnetic resonance imaging; Q, chi-squared statistic; 
SE, standard error. 
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et al. [18] studied 140 patients (96 HFpEF, 44 controls) using cardiac 
MRI. 42 (44%) of 96 HFpEF patients reached the primary endpoint (14 
deaths, 28 hospitalisations). They used indexed ECV, which is the 
product of the percentage of ECV multiplied by the indexed left ven-
tricular end-diastolic volume (LVEDV) (iECV = ECV (%) × indexed 
LVEDV). HFpEF patients had greater diffuse fibrosis (iECV = 13.7 ± 4.4 
ml/m2) than controls (iECV = 10.9 ± 2.8 ml/m2) (P < 0.0001). In 
multivariate analysis, iECV was an independent predictor of outcome 
(HR = 1.689, 95% CI 1.141–2.501, P = 0.009). Overall, 92 (33.5%) of 
274 recruited patients for cardiac MRI prognostication reached the 
primary endpoint. 
Therefore, the detection of diffuse myocardial fibrosis by increased 
T1 or increased ECV are markers of major cardiovascular events and 
death in patients with HFpEF (Table 3). Nevertheless, more evidence 
and standardisation is warranted for a clearer clinical translation of 
quantitative mapping techniques for further characterisation of the 
myocardium. 
4.3. Stress cardiac MRI 
Kanagala et al. [6] observed cardiac MRI’s superiority over echo-
cardiography (TTE) in detecting hidden pathology among 154 patients 
with HFpEF using first-pass stress perfusion cardiac MRI. Having 
excluded patients with known cardiac and non-cardiac pathology that 
could adversely affect the prognosis, 42 (27%) patients had an undiag-
nosed pathology. These included - coronary artery disease [20], 
microvascular dysfunction [11], hypertrophic cardiomyopathy [10], 
and constrictive pericarditis [5]. Patients with HFpEF who had newly 
added diagnoses had a worse prognosis during follow up (Log-rank test, 
P = 0.047). 53 of 154 patients reached the primary endpoint, in which 
20 (38%) of the 53 patients were of the ‘newly diagnosed pathology’ 
group by cardiac MRI. On multivariate Cox proportional hazards anal-
ysis, patients with a new diagnosis had the most powerful predictors of 
outcome (HR = 1.92, 95% CI = 1.07–3.45, P = 0.03). 
In addition to myocardial ischaemia, the use of stress cardiac MRI 
uncovered associated pathology in patients with HFpEF, which identi-
fied patients with a higher risk of major cardiovascular events, including 
death (Table 3). 
4.4. Right ventricular systolic dysfunction (RVSD) 
A strong correlation between right ventricular systolic dysfunction 
(RVEF <45%) and prognosis in HFpEF was reported by Aschauer et al. 
[16]. Using univariable and multivariable Cox analysis, RVSD was 
markedly linked with reduced event-free survival (HR = 4.90, 95% CI 
2.46–9.75, P < 0.001). 
4.5. Clinical perspective 
This systematic review and meta-analysis identified LGE, T1 map-
ping, stress cardiac MRI and detection of RVSD as four cardiac MRI 
derived markers of risk of MACE and mortality in patients with HFpEF. 
These, along with the robust characteristics of the diagnostic abilities of 
cardiac MRI do call for re-configuration of the workup of patients with 
HFpEF. 
Cardiac MRI provides the capabilities not only of confirming that the 
left ventricular ejection is preserved along with inevitable dilatation of 
the left atrium seen in patients with HFpEF; it provides information 
about possible aetiology or other by-stander pathologies that could alter 
the prognosis. It detects scarring known to be associated with increased 
risk of arrhythmia and may predict reduced responsiveness to thera-
peutics of heart failure. The systemic review and meta-analysis identi-
fied a threshold for LGE beyond which there is an increased risk of MACE 
and mortality (Table 4). Similarly, the detection of diffuse fibrosis by T1 
mapping was demonstrated to be associated with increased risk of 
MACE, including mortality, particularly once a certain threshold was 
crossed (Table 4). Other findings such as ischaemia and RVSD were 
proved to be vital additions in the prediction of poor outcome. 
The heterogeneity of LGE imaging makes it less attractive for the 
clinical translation in prognostication of patients with HFpEF. However, 
in our study, tissue mapping techniques, which inherently are quanti-
tative methods, demonstrate lower heterogeneity and are more appro-
priate for clinical translation. This does not come as a surprise bearing in 
mind they remove the heterogeneity of the qualitative imaging data. 
Thus, we believe that cardiac MRI should be routinely considered as 
an essential tool in the workup of patients diagnosed with HFpEF to at 
least inform the prognosis and potentially to select patients in the future 
to be enrolled in studies of therapeutics designed to reduce the risk of 
heart failure hospitalisation. 
4.6. Limitations 
In this systematic review and meta-analysis, we did not include 
studies specifically looking at the diagnostic accuracy of any cardiac 
MRI metric for HFpEF. Hence, we did not report studies which have 
done sensitivity/specificity analysis. Caution should be applied in the 
judgement of meta-analysis where heterogeneity was greater than 75%. 
Future studies need a clearer framework for acquisition and post- 
processing to limit this heterogeneity for clinical translation. Due to 
the lack of significant number of studies representing stress cardiac MRI 
and right ventricular assessment for prognostication in HFpEF, we have 
combined them into a ‘heterogenous’ group. The results of this hetero-
geneous group are only hypothesis generating and caution should be 
applied for considerable judgement of the results. More studies are 
Table 4 
Summary of clinically relevant cut-offs for several cardiac MRI metrics which 
have prognostic significance.  








LGE LGE volume 
5.7% 
Signal intensity >5 SD 
above the mean signal 




LGE LGE volume 
6% 
Signal intensity >2 SD 
above the mean signal 




LGE LGE volume 
≥ 17% 
Visual scoring on AHA 17- 
segment model of the LV 
Kanagala P. 
2019 
iECV\ECV iECV >16.8 
ml/m2 
ECV >30.7 




ECV ECV >29% ECV = λ × (1 −





ECV ECV >28.9% ECV = λ × (1 −






Post-contrast T1 T1 time <
388.3 ms 










Full clinical assessment 
leading to new diagnosis 
Aschauer S. 
2016 
RVSD RV EF <45% Standard volumetric 
contours 
Abbreviations: AHA, american heart association; CI, confidence interval; ECV, 
extracellular volume; FU, follow-up (in months); HR, hazard ratio; iECV, total 
extracellular volume of the myocardium indexed to body surface area; LGE, late 
gadolinium enhancement; LV, left ventricle; LVEDV, left ventricular end- 
diastolic volume; MRI, magnetic resonance imaging; RVEF, right ventricle 
ejection fraction; RVSD, right ventricular systolic dysfunction; SD, standard 
deviation. 
H. Assadi et al.                                                                                                                                                                                                                                  
Magnetic Resonance Imaging 76 (2021) 116–122
122
warranted exploring multi-parametric cardiac MRI utility in prognosti-
cation of patients with HFpEF. 
5. Conclusion 
This meta-analysis demonstrates that multiparametric cardiac MRI 
has value in prognostication of patients with HFpEF. HFpEF patients 
with a detectable scar on LGE, fibrosis on T1-mapping, myocardial 
ischaemia or RVSD appear to have a worse prognosis. 
5.1. Key messages 
What is already known about this subject?  
● Cardiac magnetic resonance imaging (MRI) is emerging as an 
important imaging tool in the assessment of heart failure with pre-
served ejection fraction (HFpEF). 
What does this study add?  
● Evidence gathered in this systematic review and meta-analysis 
demonstrates that multiparametric cardiac MRI has value in the 
prognostication of patients with HFpEF.  
● HFpEF patients with a detectable scar on LGE, fibrosis on T1- 
mapping, myocardial ischaemia or RVSD appear to have a worse 
prognosis. 
How might this impact on clinical practice? 
● Cardiac MRI should be considered in the diagnostic work-up of pa-
tients with suspected HFpEF. Cardiac MRI not only allows for better 
sub-phenotyping of HFpEF, but also to risk stratify HFpEF patients 
depending on cardiac MRI characteristics. 
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